MGNX Stock Summary and Trading Ideas (Macrogenics | NASDAQ:MGNX)

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).

Macrogenics trades on the NASDAQ stock market under the symbol MGNX.

As of April 19, 2024, MGNX stock price declined to $15.61 with 1,004,474 million shares trading.

MGNX has a beta of 1.27, meaning it tends to be more sensitive to market movements. MGNX has a correlation of 0.05 to the broad based SPY ETF.

MGNX has a market cap of $974.56 million. This is considered a Small Cap stock.

In the last 3 years, MGNX stock traded as high as $36.48 and as low as $2.13.

The top ETF exchange traded funds that MGNX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.

MGNX has outperformed the market in the last year with a return of +128.6%, while the SPY ETF gained +21.2%. In the last 3 month period, MGNX beat the market returning +30.1%, while SPY returned +3.0%. However, in the most recent 2 weeks MGNX has underperformed the stock market by returning -14.4%, while SPY returned -4.5%.

MGNX support price is $15.38 and resistance is $16.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MGNX stock will trade within this expected range on the day.